- Home
- GAU vs PACB Comparison
GAU vs PACB Comparison
Compare GAU & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | PACB |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.8M | 521.8M |
| IPO Year | 2006 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GAU | PACB |
|---|---|---|
| Price | $2.27 | $1.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.08 | $1.67 |
| AVG Volume (30 Days) | 2.8M | ★ 7.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $82.77 | $11.32 |
| Revenue Next Year | $29.09 | $12.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $1.66 | $1.07 |
| 52 Week High | $3.62 | $2.73 |
Technical Indicators
Market Signals| Indicator | GAU | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 47.26 |
| Support Level | $2.14 | $1.27 |
| Resistance Level | $2.45 | $1.47 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 67.78 | 35.71 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.